8-K: Cassava Sciences Reports Q1 2025 Financial Results and Business Update; Shifts Focus to TSC-Related Epilepsy

Cassava Sciences announces Q1 2025 financial results, highlights a new license agreement with Yale University, leadership appointments, and a strategic shift towards developing simufilam for TSC-related epilepsy.

Summary

• Cassava Sciences reported its Q1 2025 financial results and provided a business update on May 8, 2025.
• The company is shifting its focus to developing simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy.
• A license agreement with Yale University provides intellectual property rights for potential treatments for certain rare diseases, including TSC-related epilepsy.
• The company appointed Dr. Anglique Bordey as SVP, Neuroscience, and Dr. Jack Moore as SVP, Clinical Development.
• Cassava plans to initiate the first clinical study in TSC-related epilepsy in the first half of 2026, pending pre-clinical studies and regulatory strategy development.
• The Alzheimer's disease program with simufilam will be completely discontinued by the end of the second quarter of 2025 after the RETHINK-ALZ and REFOCUS-ALZ Phase 3 studies did not meet their co-primary endpoints.
• At March 31, 2025, cash and cash equivalents were $117.3 million, with no debt.
• Net loss for Q1 2025 was $23.4 million, compared to a net income of $25.0 million for the same period in 2024.
• Net cash used in operations was $11.3 million during the first quarter of 2025.
• Net cash used in operations for the first half of 2025 is expected to be $16 to $20 million.
• Research and development (R&D) expenses were $13.7 million, a 16% decrease compared to $16.2 million in Q1 2024.
• General and administrative (G&A) expenses were $10.9 million, compared to $3.7 million for the same period in 2024.
• The company reduced its workforce by 10 employees, or approximately 33%, in the first quarter as part of a cost curtailment program.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the discontinuation of the Alzheimer's program and the reported net loss, although the focus on TSC-related epilepsy and the strong cash position provide some positive aspects.

Positives

• Cassava Sciences has a strong cash position of $117.3 million with no debt.
• The company is expanding its pipeline by pursuing a new therapeutic application for simufilam in TSC-related epilepsy.
• The company has appointed experienced neuroscience and clinical development experts to advance the TSC-related epilepsy program.
• The company expects net cash used in operations for the first half of 2025 to be $16 to $20 million, consistent with previous guidance.

Negatives

• The Alzheimer's disease program with simufilam is being discontinued after Phase 3 studies failed to meet co-primary endpoints.
• Cassava Sciences reported a net loss of $23.4 million for Q1 2025, compared to a net income of $25.0 million for the same period in 2024.
• General and administrative expenses increased significantly due to legal related expenses, including a $3.0 million estimated loss accrual.
• The company reduced its workforce by approximately 33% in Q1 as part of a cost curtailment program.

Risks

• The development of simufilam for TSC-related epilepsy is subject to the risks inherent in drug discovery and development.
• Clinical trials may not be successful, and regulatory approval may not be obtained.
• The company's future financial performance is subject to a number of risks, uncertainties, and assumptions.
• The company is exposed to risks relating to its ability to successfully carry out its obligations under the Yale License Agreement.
• The company is exposed to risks relating to its ability to efficiently discontinue its Alzheimer's disease development program.

Future Outlook

Cassava Sciences plans to initiate clinical trials for simufilam in TSC-related epilepsy in the first half of 2026, pending pre-clinical studies and regulatory strategy development. The company expects net cash used in operations for the first half of 2025 to be $16 to $20 million.

Management Comments

• Rick Barry, President and Chief Executive Officer of Cassava, stated that the license with Yale University and the appointments of Dr. Bordey and Dr. Moore position the company to advance toward a clinical trial program in TSC with diligence.
• Eric Schoen, Chief Financial Officer of Cassava, added that Cassava remains committed to its mission of developing novel medicines for central nervous system diseases, while maintaining continued strategic expense management.

Industry Context

Cassava's shift towards TSC-related epilepsy reflects a strategic pivot to address unmet needs in rare CNS disorders, potentially offering a new avenue for growth after setbacks in Alzheimer's disease. This move aligns with the broader industry trend of exploring niche indications with targeted therapies.

Comparison to Industry Standards

• Comparing Cassava's cash position of $117.3 million to other clinical-stage biotech companies, it appears relatively strong, providing runway for planned clinical trials.
• The discontinuation of the Alzheimer's program is similar to other companies that have faced setbacks in this challenging therapeutic area, such as Biogen and Eisai with Aduhelm, highlighting the high risk and complexity of Alzheimer's drug development.
• The planned clinical trial initiation in H1 2026 for TSC-related epilepsy is a typical timeline for early-stage clinical development, comparable to other companies developing therapies for rare diseases.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term negative impact due to the discontinuation of the Alzheimer's program and reported net loss.
• Employees were impacted by a workforce reduction of approximately 33%.
• Patients with TSC-related epilepsy may benefit from the development of simufilam as a potential treatment.

Next Steps

• Conduct pre-clinical studies of simufilam relating to seizures in TSC.
• Develop a regulatory strategy for simufilam in TSC-related epilepsy.
• Initiate clinical studies with simufilam in H1 2026 for TSC-related epilepsy.
• Wind down the Alzheimer's disease program by the end of the second quarter of 2025.

Key Dates

Keywords

Cassava Sciences, Simufilam, TSC-related epilepsy, Alzheimer's disease, Clinical trials, Financial results, Biotechnology, CNS disorders, R&D, Net loss, Cash position